In recent years, five prospective randomised clinical trials showed clinical benefits for erlotinib [26], [27] and gefitinib [28]–[30] in EGFR mutation-positive NSCLC, pemetrexed had demonstrated superior general efficacy to a range of comparators [31]–[34], and in patients with advanced NSCLC, rh-endostatin plus platinum-based chemotherapy has shown significantly longer PFS [35], [36]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.